Drug Trial Radar · NCT06155422
A Prospective Real-world Study of Cadonilimab in Patients With Recurrent or Metastatic Cervical Cancer
Last checked: Nov 20, 2026Latest source record: Dec 4, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
670
Planned (sponsor's estimate)
Start
Nov 30, 2023
Primary completion
Nov 30, 2026
Study completion Nov 30, 2027
Sponsor
- Lead sponsor
- Gang Chen (101199)Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 4, 2023
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This real-world study included all patients with recurrent or metastatic cervical cancer who used Cadonilimab in clinical practice, regardless of treatment lines and combination with different treatments. Through follow-up observations, the aim of this study is to analyze the efficacy of Cadonilimab for recurrent or metastatic cervical cancer in the real world, and to explore the differences in the efficacy of Cadonilimab in different stages of treatment, as well as the efficacy of different treatment combinations, so as to provide clinical evidence for the use of Cadonilimab for recurrent or metastatic cervical cancer.
Conditions
- Recurrent or Metastatic Cervical Cancer
Interventions
CadonilimabDrug
recurrent or metastatic cervical cancer in the first, second or third lines Systematic treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR)Time frame: from the first drug administration up to two years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.